[Whitepaper] Funding Treatments for Rare Diseases

In Orphan Drug Congress, Whitepapers by Freya Smale

Orphan drugs (OD) can cost hundreds of thousands of dollars annually.

Download white paper now >

Introduction to the WODC Payer Workshop on March 20

At the WODC meeting in Washington on April 20 2016, PPi HC will be chairing a full day event on the important topic of funding treatments for rare diseases. This very sensitive area is a greatly contentious one, and so we are very proud to bring together a highly prestigious payer panel consisting of experts and payers from the US, UK, France, Italy, Australia and Bulgaria.

Download white paper now >

Concessions and incentives to support the development of ODs include the following, but there are many countries where such concessions do not extend to payer decision-making on pricing and reimbursement (P&R), including Health Technology Assessment (HTA).

  •  Extended market exclusivity (7-10 years)
  •  Tax and fee reductions (clinical trials, inspections, MAs)
  •  Protocol assistance, free advice
  •  Research grants
  •  Central European filing / expedited regulatory review
  •  Single format annual report to either FDA or EMA

We are thrilled to announce that PPi Healthcare Consulting are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.

World Orphan Drug Congress USA 2016